SynthesisFrontiers in immunology2022
Duration of immunity to SARS-CoV-2 in children after natural infection or vaccination in the omicron and pre-omicron era: A systematic review of clinical and immunological studies.
Synthesis in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Comparative analysis of adaptive immunity to SARS-CoV-2 in infected children and adults.Pediatric research · 2026Article
- Protection From COVID-19 Vaccination and Prior SARS-CoV-2 Infection Among Children Aged 6 Months-4 Years, United States, September 2022-April 2023.Journal of the Pediatric Infectious Diseases Society · 2025Article
- Assessing the Value of T cell Monitoring in the General Population of Children and Adolescents - Insights From the Ciao Corona Cohort Study.International journal of public health · 2025Observational
- Long COVID in pediatric age: an observational, prospective, longitudinal, multicenter study in Italy.Frontiers in immunology · 2025Observational
- Characteristics and predictors of Long Covid in children: a 3-year prospective cohort study.EClinicalMedicine · 2024Article
- Determinants of Undernutrition among Children Admitted to a Pediatric Hospital in Port Sudan, Sudan.Nutrients · 2024Article
- Factors associated with elevated SARS-CoV-2 immune response in children and adolescents.Frontiers in pediatrics · 2024Article
- Observational
- Acute labyrinthitis: a manifestation of COVID-19 in a teenager.BMJ case reports · 2023Article
- Persistent humoral immune response in youth throughout the COVID-19 pandemic: prospective school-based cohort study.Nature communications · 2023Article
- Venous Thromboembolism After COVID-19 Infection Among People With and Without Immune-Mediated Inflammatory Diseases.JAMA network open · 2023Article
- BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.The Lancet. Child & adolescent health · 2023Article
- Article
- Review
- Pediatric humoral immune responses and infection risk after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and two-dose vaccination during SARS-CoV-2 omicron BA.5 and BN.1 variants predominance in South Korea.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Duration of humoral and cellular memory in children previously infected SARS-CoV-2 or vaccinated and subsequent risk of reinfection is still not fully elucidated. Methods: Systematic review of studies retrieved from medical databases and article reference lists. Results: From 2420 identified articles, 24 met the inclusion criteria. Children infected during the pre-omicron era developed long lasting (at least 10-12 months) humoral and cellular immunity against pre-Omicron SARS-CoV-2 variants, but have reduced Conclusions: Available evidence, although limited, suggested a long-lasting but unperfect protection of previous infections or vaccination against pre-Omicron and Omicron variants. Based on our findings, it might be reasonable to offer families of children infected before Omicron a booster vaccination. A similar indication should be proposed also for those infected with Omicron, specifically for more fragile children at higher risk of COVID-19-related complications, based on better cross-variant neutralisation induced by vaccination. Systematic review registration: PROSPERO, identifier ID 353189.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.